Saxena Nishant C 4

What Happened
Nishant C. Saxena, Chief Business Officer of Corbus Pharmaceuticals (CRBP), made open-market purchases of company stock on June 2–3, 2026. He bought 4,500 shares on 2026-06-02 at about $7.33 per share ($32,999) and 9,000 shares on 2026-06-03 at $7.58 per share ($68,220), for a total of 13,500 shares purchased for roughly $101,219. These were purchases (transaction code P), which investors often view as a more informative signal than routine sales.

Key Details

• Transaction dates and prices:
  • 2026-06-02: 4,500 shares @ $7.33 — ~$32,999
  • 2026-06-03: 9,000 shares @ $7.58 — ~$68,220
  • Total: 13,500 shares for ~ $101,219
• Transaction type: Open-market purchases (SEC code P).
• Holdings after transaction: The filing notes that the reported holdings include 58,300 unvested RSUs subject to a vesting schedule (Footnote F2). Refer to the Form 4 for the exact "amount owned following" figure reported.
• Notable footnote (F1): The price(s) reported are weighted averages for multiple trades; some purchases occurred at prices in a narrow range (e.g., $7.33–$7.34). The reporting person will provide the breakdown of individual trade prices on request.
• Timeliness: Report filed 2026-06-03 for trades on 2026-06-02 and 2026-06-03 — appears to have been filed within the usual SEC reporting window.

Context
These were straightforward open-market purchases by an executive (CBO). Purchases by insiders can be informative because they reflect executives adding to their positions, but they are not proof of future performance. There were no option exercises, gifts, or tax-withholding-related withholdings disclosed in this filing. For full details, see the Form 4 (Accession no. 0001193125-26-255834).